Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
31. Oktober 2023 09:00 ET
|
Gracell Biotechnologies Inc.
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment...
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
30. Oktober 2023 08:30 ET
|
Gracell Biotechnologies Inc.
Gracell Biotechnologies to Report Q3 2023 Business Updates on November 13
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
27. September 2023 08:30 ET
|
Gracell Biotechnologies Inc.
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting 100%...
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
26. September 2023 16:00 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
19. September 2023 09:21 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
14. September 2023 09:15 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
24. August 2023 16:10 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
14. August 2023 07:15 ET
|
Gracell Biotechnologies Inc.
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to...
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
31. Juli 2023 16:02 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
31. Juli 2023 09:00 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company...